BioCentury | Jan 29, 2019
Distillery Techniques


TECHNOLOGY: Gene profiling; tissue markers Expression levels of a five-gene signature in lung carcinoma in situ lesions could help predict progression to squamous cell lung carcinoma. In biopsy samples from 51 patients with lung carcinoma...
BioCentury | Jul 25, 2017
Distillery Therapeutics


INDICATION: Pancreatic cancer Cell culture and mouse studies suggest inhibiting PARP in combination with ELAVL1 could help treat pancreatic ductal adenocarcinoma (PDAC). In two human PDAC cell lines treated with the PARP inhibitors Lynparza olaparib...
BioCentury | Mar 31, 2016
Distillery Therapeutics

Therapeutics: Elav like RNA binding protein 1 (ELAVL1)

Cancer INDICATION: Ovarian cancer Patient sample and mouse studies suggest inhibiting ELAVL1 could help treat ovarian cancer. ELAVL1 levels were higher in primary tumors from ovarian cancer patients than in ovarian tissue from healthy controls....
Items per page:
1 - 3 of 3